Literature DB >> 23067077

Linear IgA bullous dermatosis: report of five cases in Chile.

Mauricio Sandoval1, María Magdalena Farias, Sergio Gonzalez.   

Abstract

BACKGROUND: Linear IgA bullous dermatosis (LABD) is an acquired autoimmune sub-epidermal vesiculobullous disease characterized by continuous linear IgA deposit on the basement membrane zone, as visualized on direct immunofluorescence microscopy. LABD can affect both adults and children. The disease is very uncommon, with a still unknown incidence in the South American population.
MATERIALS AND METHODS: All confirmed cases of LABD by histological and immunofluorescence in our hospital were studied.
RESULTS: The confirmed cases were three females and two males, aged from 8 to 87 years. Precipitant events associated with LABD were drug consumption (non-steroid inflammatory agents in two cases) and ulcerative colitis (one case). Most of our patients were treated with dapsone, resulting in remission. DISCUSSION: Our series confirms the heterogeneous clinical features of this uncommon disease in concordance with a larger series of patients reported in the literature.
© 2012 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2012        PMID: 23067077     DOI: 10.1111/j.1365-4632.2011.05324.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Ten-year follow-up study of linear immunoglobulin A dermatosis complicated with ulcerative colitis.

Authors:  Hiroki Sonoyama; Yoshiyuki Mishima; Shunji Ishihara; Naoki Oshima; Ichiro Moriyama; Kousaku Kawashima; Yuko Chinuki; Eishin Morita; Yoshikazu Kinoshita
Journal:  Clin J Gastroenterol       Date:  2019-09-25

Review 2.  Linear Immunoglobulin a Bullous Dermatosis in Children.

Authors:  Francesca Mori; Francesca Saretta; Lucia Liotti; Mattia Giovannini; Riccardo Castagnoli; Stefania Arasi; Simona Barni; Carla Mastrorilli; Luca Pecoraro; Lucia Caminiti; Gian Luigi Marseglia; Annick Barbaud; Elio Novembre
Journal:  Front Pediatr       Date:  2022-07-08       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.